Bioxcel- Nektar and Merck KGaA in a Triple Collaboration for Pancreatic Cancer
Shots:
- The companies entered into a clinical collaboration for evaluating BioXcel’s BXCL701- Nektar’s NKTR-214 & Avelumab (co-developed and co-commercialized by Merck KGaA and Pfizer) as a triple combination therapy for pancreatic cancer
- In Nov-2017- BTI and Nektar Therapeutics initially collaborated for preclinical development and expand their collaboration on 24 Sept-2018 for novel triple combination therapy
- Under the collaboration- BTI will be responsible for the clinical development & Nektar will equally share development cost of novel triple combination therapy
Ref: Ascendis Pharma | Image: Merck KGaA
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com